🇺🇸 FDA
Patent

US 11912997

RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use

granted A61KA61K45/06A61K47/543

Quick answer

US patent 11912997 (RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K45/06, A61K47/543, A61P, A61P25/28